Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
CLEVELAND, April 12, 2018 -- Athersys, Inc. (Nasdaq:ATHX) will release its first quarter 2018 financial results at approximately 4:00 PM Eastern Time on Thursday, May 10, 2018, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:
| Date | May 10, 2018 |
| Time | 4:30 p.m. (Eastern Time) |
| Telephone access: US and Canada | (800) 273-1254 |
| Telephone access: International | (973) 638-3440 |
| Access code | 1189915 |
| Live webcast | www.athersys.com under Investors section |
A replay will be available for on-demand listening shortly after the completion of the call until 11:59 PM Eastern Time on May 24, 2018 at the aforementioned URL, or by dialing (800) 585-8367 or (855) 859-2056 in the U.S. and Canada, or from abroad (404) 537-3406, and entering access code 1189915.
About Athersys
Athersys is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, cardiovascular, and inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance the MultiStem cell therapy toward commercialization. More information is available at www.athersys.com.
ATHX-G
Contact:
William (B.J.) Lehmann, J.D.
President and Chief Operating Officer
Tel: (216) 431-9900
[email protected]
Karen Hunady
Corporate Communications and Investor Relations
Tel: (216) 431-9900
[email protected]
David Schull
Russo Partners, LLC
Tel: (212) 845-4271 or (858) 717-2310
[email protected]
